Heyltex Corporation specializes in the development, manufacturing & international distribution of medical countermeasures for radiological public health emergencies. In cooperation with Heyl chem. pharm. Fabrik Berlin, Heyltex has developed an antidote against Cesium-137 which is the only antidote against Cesium-137 approved by the U.S. Food and Drug Administration. Ca-DTPA, Zn-DTPA and other chelating agents are also part of our portfolio. Heyltex’ newly launched product, eventPOD™, aims to bring antidotes together in a module which temporarily increases medical preparedness of organizers of High Visibility Events (HVE).